328 related articles for article (PubMed ID: 19539482)
1. Proteochemometrics mapping of the interaction space for retroviral proteases and their substrates.
Kontijevskis A; Petrovska R; Yahorava S; Komorowski J; Wikberg JE
Bioorg Med Chem; 2009 Jul; 17(14):5229-37. PubMed ID: 19539482
[TBL] [Abstract][Full Text] [Related]
2. Comparison of inhibitor binding to feline and human immunodeficiency virus proteases: structure-based drug design and the resistance problem.
Dunn BM; Pennington MW; Frase DC; Nash K
Biopolymers; 1999; 51(1):69-77. PubMed ID: 10380354
[TBL] [Abstract][Full Text] [Related]
3. A look inside HIV resistance through retroviral protease interaction maps.
Kontijevskis A; Prusis P; Petrovska R; Yahorava S; Mutulis F; Mutule I; Komorowski J; Wikberg JE
PLoS Comput Biol; 2007 Mar; 3(3):e48. PubMed ID: 17352531
[TBL] [Abstract][Full Text] [Related]
4. Proteochemometric modeling reveals the interaction site for Trp9 modified alpha-MSH peptides in melanocortin receptors.
Lapinsh M; Prusis P; Petrovska R; Uhlén S; Mutule I; Veiksina S; Wikberg JE
Proteins; 2007 May; 67(3):653-60. PubMed ID: 17357163
[TBL] [Abstract][Full Text] [Related]
5. Computational proteomics analysis of HIV-1 protease interactome.
Kontijevskis A; Wikberg JE; Komorowski J
Proteins; 2007 Jul; 68(1):305-12. PubMed ID: 17427231
[TBL] [Abstract][Full Text] [Related]
6. A structural model for the retroviral proteases.
Pearl LH; Taylor WR
Nature; 1987 Sep 24-30; 329(6137):351-4. PubMed ID: 3306411
[TBL] [Abstract][Full Text] [Related]
7. Design and evaluation of substrate-based octapeptide and non substrate-based tetrapeptide inhibitors of dengue virus NS2B-NS3 proteases.
Prusis P; Junaid M; Petrovska R; Yahorava S; Yahorau A; Katzenmeier G; Lapins M; Wikberg JE
Biochem Biophys Res Commun; 2013 May; 434(4):767-72. PubMed ID: 23587903
[TBL] [Abstract][Full Text] [Related]
8. Exploiting new genome data and Internet resources for the phylogenetic analysis of proteases, substrates and inhibitors.
Southan C
Biochem Soc Trans; 2007 Jun; 35(Pt 3):599-603. PubMed ID: 17511660
[TBL] [Abstract][Full Text] [Related]
9. Proteochemometric modeling of drug resistance over the mutational space for multiple HIV protease variants and multiple protease inhibitors.
Lapins M; Wikberg JE
J Chem Inf Model; 2009 May; 49(5):1202-10. PubMed ID: 19391634
[TBL] [Abstract][Full Text] [Related]
10. Protease proteomics: revealing protease in vivo functions using systems biology approaches.
Doucet A; Overall CM
Mol Aspects Med; 2008 Oct; 29(5):339-58. PubMed ID: 18571712
[TBL] [Abstract][Full Text] [Related]
11. Characterization of bacterial proteases with a panel of fluorescent peptide substrates.
Wildeboer D; Jeganathan F; Price RG; Abuknesha RA
Anal Biochem; 2009 Jan; 384(2):321-8. PubMed ID: 18957278
[TBL] [Abstract][Full Text] [Related]
12. Retroviral proteases and their roles in virion maturation.
Konvalinka J; Kräusslich HG; Müller B
Virology; 2015 May; 479-480():403-17. PubMed ID: 25816761
[TBL] [Abstract][Full Text] [Related]
13. Proteochemometrics analysis of substrate interactions with dengue virus NS3 proteases.
Prusis P; Lapins M; Yahorava S; Petrovska R; Niyomrattanakit P; Katzenmeier G; Wikberg JE
Bioorg Med Chem; 2008 Oct; 16(20):9369-77. PubMed ID: 18824362
[TBL] [Abstract][Full Text] [Related]
14. Evolutionary optimization of peptide substrates for proteases that exhibit rapid hydrolysis kinetics.
Boulware KT; Jabaiah A; Daugherty PS
Biotechnol Bioeng; 2010 Jun; 106(3):339-46. PubMed ID: 20148412
[TBL] [Abstract][Full Text] [Related]
15. Amino acid preferences of retroviral proteases for amino-terminal positions in a type 1 cleavage site.
Eizert H; Bander P; Bagossi P; Sperka T; Miklóssy G; Boross P; Weber IT; Tözsér J
J Virol; 2008 Oct; 82(20):10111-7. PubMed ID: 18701588
[TBL] [Abstract][Full Text] [Related]
16. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
Kontijevskis A; Komorowski J; Wikberg JE
J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
[TBL] [Abstract][Full Text] [Related]
17. Viral proteins and site-specific cleavage.
Korant BD; Lonberg-Holm KK
Acta Biol Med Ger; 1981; 40(10-11):1481-8. PubMed ID: 6177137
[TBL] [Abstract][Full Text] [Related]
18. Synthetic peptides as substrates and inhibitors of a retroviral protease.
Kotler M; Katz RA; Danho W; Leis J; Skalka AM
Proc Natl Acad Sci U S A; 1988 Jun; 85(12):4185-9. PubMed ID: 2837759
[TBL] [Abstract][Full Text] [Related]
19. Protein-protein interactions as targets for antiviral chemotherapy.
Loregian A; Marsden HS; Palù G
Rev Med Virol; 2002; 12(4):239-62. PubMed ID: 12125015
[TBL] [Abstract][Full Text] [Related]
20. Design of peptidomimetic inhibitors of aspartic protease of HIV-1 containing -Phe Psi Pro- core and displaying favourable ADME-related properties.
Frecer V; Berti F; Benedetti F; Miertus S
J Mol Graph Model; 2008 Oct; 27(3):376-87. PubMed ID: 18678515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
